Posttreatment ctDNA positivity correlates with worse relapse-free survival and earlier recurrence in patients with locally advanced cervical cancer, real-world data show.

Multiple myeloma is the second most common blood cancer in adults. It starts in the white blood cells that are responsible ...

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...

By Sneha S K April 13 (Reuters) - Allogene Therapeutics said on Monday that interim data from a mid-stage study showed its experimental off-the-shelf CAR-T therapy reduced the risk of cancer relapse ...

Dr Gordon discusses use of bispecifics for management of patients with relapsing DLBCL. Leo Gordon, MD: In relapsed disease, I think most patients who relapse, or they relapse say 3 or 4 years later, ...

Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study ...

Nearly everyone with multiple myeloma relapses. That doesn’t make it easy. A cancer diagnosis is traumatic, especially when the cancer is treatable, but not curable. In multiple myeloma, the disease ...

Development of mixed histiocytosis (Langerhans cell histiocytosis (LCH))/Erdheim–Chester disease (ECD)) after treatment in patients with an initial skull LCH lesion has not been well recognized. An ...